You have no items in your shopping cart.
On Promotion
Elisa Kits Promotion 1
Products on Sale 0
Category
Antibodies 1300
Proteins and Peptides 1287
Small Molecules 322
Tools 74
Assays and Kits 43
Species Host
Rabbit 388
Mouse 269
Human 160
Goat 30
E. coli 28
Mammal 24
Plant 8
Camelus 6
Gallus 1
Tested Applications
ELISA 1085
WB 670
IF 120
EIA 57
IHC 55
NeA 53
Blocking 50
FC 50
SDS-PAGE 36
Kinetics 33
MS 32
IHC-P 23
IP 19
LF 14
GICA 11
ICC 11
CLIA 8
Functional Studies 7
IA 7
In vivo 6
Crystallography 5
Control 4
DOT 4
IHC-Fr 3
FA 2
FACS 2
Reactivity
Virus 852
Human 186
Other 55
Mouse 52
Rat 19
Hamster 3
Primate 2
All 1
Camelus 1
Predicted Reactivity
Virus 134
Bovine 6
Canine 1
Equine 1
Guinea 1
Mouse 1
Pig 1
Rabbit 1
Rat 1
Zebrafish 1
Conjugation
Unconjugated 1060
Biotin 69
HRP 62
AP 31
PE 17
FITC 16
APC 15
Cy3 15
iFluor647 14
AE 7
IRDye800 4
APC/Cy5.5 1
APC/Cy7 1
BF350 1
BF405 1
BF488 1
BF555 1
BF594 1
BF647 1
BF680 1
BF750 1
Cy5 1
Cy5.5 1
Cy7 1
PE/Cy5 1
PE/Cy5.5 1
PE/Cy7 1
PerCP 1
PerCP/Cy5.5 1
PerCP/Cy7 1
RBITC 1
Clonality
Monoclonal 660
Polyclonal 453
Recombinant 178
Matched Antibody
Yes 0
No 3026
Featured Product
Yes 355
Has Publications
Yes 1
No 3025
Search results for: 'Cov'
98.00%
26.52 kDa (predicted); 37.75 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation N501S) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. Predicted N terminal: Arg 319
C-His
100 μg98.00%
133.72 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations P26S, HV69-70del, V126A, Y144 deletion, LLA241-243 deletion, H245Y, S477N, E484K, D614G, P681H, T1027I, D1118H) (Met1-Pro1213) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.620) which emerged in the Cameroon. Predicted N terminal: Val 16
C-His
100 μg98.00%
46.69 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Nucleocapsid (YP_009724397.2, with mutations P13L, R203K, G204R, Q384H) (Met1-Ala419) was expressed with a polyhistidine tag at the N-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant C.1.2) which emerged in the South Africa. Predicted N terminal: Met
N-His
100 μg98.00%
133.58 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations G75V, T76I, RSYLTPD246-252 deletion, D253N, L452Q, F490S, D614G, T859N) (Met1-Pro1213) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant C.37) which emerged in the Peru. Predicted N terminal: Val 16
C-His
100 μg98.00%
51.84 kDa (predicted); 56.07 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations R346K, E484K, N501Y) (Arg319-Phe541) was expressed with the Fc region of human IgG1 at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.621) which emerged in the South America. Predicted N terminal: Arg 319
C-Fc
100 μg98.00%
51.78 kDa (predicted); 60.49 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations L452Q, F490S) (Arg319-Phe541) was expressed with the Fc region of human IgG1 at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant C.37) which emerged in the Peru. Predicted N terminal: Arg 319
C-Fc
100 μg98.00%
34.10 kDa (predicted); 51.01 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 NTD (YP_009724390.1, with mutations T19R, T95I, G142D, 156-157 deletion, R158G) (Met1-Ser305) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617.2) which emerged in the India. Predicted N terminal: Val 16
C-His
100 μg98.00%
76.36 kDa (predicted); 109.57 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.621) which emerged in the South America. Predicted N terminal: Val 16
C-His
100 μg98.00%
75.77 kDa (predicted); 111.88 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations P26S, HV69-70 deletion, V126A, Y144 deletion, LLA241-243 deletion, H245Y, S477N, E484K, D614G, P681H) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.620) which emerged in the Cameroon. Predicted N terminal: Val 16
C-His
100 μg98.00%
26.57 kDa (predicted); 33.53 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations Y449H, E484K, N501Y) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant C.1.2) which emerged in the South Africa. Predicted N terminal: Arg 319
C-His
100 μg